Sarilumab
Sanofi,regeneron
[]
sarilumab (sar) + 14 wk gc taper demonstrated significant efficacy vs the comparator arm in steroid refractory pmr patients and improvement in quality of life. sustained remission was 28.3% sar vs 10.3% comparator arm. spiera r abs#1676 #acr22 
MD PhD Consultant Rheumatologist &Physician,Assoc Medical Director,Digital Leader,NASS Trustee &Best Rheum Care,Visiting Fellow Henley Business School,ExecCoach